| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2016-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101676622-B1 |
| titleOfInvention |
Recombinant anti-epidermal growth factor receptor antibody compositions |
| abstract |
The present invention relates to the field of recombinant antibodies for use in human cancer therapies. More particularly, the invention provides compositions or mixtures of antibodies capable of binding to human EGFR. Antibody compositions having three or more antibodies exhibit a synergistic effect in reducing the proliferation of representative cancer cell lines. In addition, beneficial results have been obtained using compositions comprising two different chimeric anti-hEGFR antibodies that exhibit rapid and effective receptor internalization, induction of terminal differentiation and novel mechanisms of action based on subsequent tumor eradication in animal models. The antibody of the present invention can be produced in a single bioreactor as a polyclonal antibody. |
| priorityDate |
2007-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |